Rosuvastatin
Small molecule targets HMGCR via inhibition
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | EZALLOR SPRINKLE | — | 2023-08-04 | fda.gov ↗ |
| Label expansions (6) | US (FDA) | CRESTOR | — | 2007-11-08 – 2016-05-27 | fda.gov ↗ |
| Approved | US (FDA) | CRESTOR | — | 2003-08-12 | fda.gov ↗ |
Trials 545 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 07 trials | ||||||
| Phase 0 | NCT06538649 | Dec 2024 → Oct 2027 expected | ileocolitis | Stanford University | Recruiting | No outcome recorded |
| Phase 0 | NCT05912387 | May 2023 → May 2027 expected | inflammatory bowel disease, primary sclerosing cholangitis | Stanford University | Recruiting | No outcome recorded |
| Phase 0 | NCT03772262 | Apr → Nov 2018 | — | Washington State University | Completed | No outcome recorded |
| Phase 0 | NCT02705547 | May 2016 → Aug 2017 | Friedreich ataxia | Children's Hospital of Philadelphia | Completed | No outcome recorded |
| Phase 0 | NCT01955759 | Dec 2013 → Dec 2014 | — | Heart Center BH Tuzla | Unknown | No outcome recorded |
| Phase 0 | NCT01881971 | May 2013 → Nov 2015 | — | Alison Morris | Completed | No outcome recorded |
| Phase 0 | NCT00689416 | Dec 2007 → Jun 2009 | atherosclerosis | AstraZeneca | Completed | No outcome recorded |
| Phase 1252 trials | ||||||
| Phase 1 | NCT07550816 | May → Dec 2026 expected | obesity disorder | Beijing QL Biopharmaceutical Co.,Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT07565441 | May → Nov 2026 expected | autosomal dominant polycystic kidney disease | Jemincare | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07692685 | May → Jun 2026 | — | Neurodawn Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07534592 | Apr → Aug 2026 overdue | — | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07515339 | Apr → Jun 2026 | chronic kidney disease | Bayer | Withdrawn | No outcome recorded |
| Phase 1 | NCT07446400 | Mar → Jun 2026 overdue | — | Otsuka Pharmaceutical Development & Commercialization, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT07431866 | Mar → Jun 2026 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT07316608 | Mar → Jun 2026 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT07378293 | Mar → Dec 2026 expected | diabetes mellitus | Shaheed Benazir Bhutto University Sheringal Dir Upper | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07389304 | Mar → Dec 2026 expected | — | Shaheed Benazir Bhutto University Sheringal Dir Upper | Not yet recruiting | No outcome recorded |
| Show all 252 trials opens the full record — a long page | ||||||
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT06553157 | Sep 2024 → Jul 2025 | cancer, platinum-induced ototoxicity | Minia University | Completed | No outcome recorded |
| Phase 1/2 | NCT04833764 | Jun 2021 → Jun 2025 | post-thrombotic syndrome, venous thromboembolism | Khanh Nguyen | Unknown | No outcome recorded |
| Phase 1/2 | NCT02314286 | Dec 2014 → Jul 2016 | severe pre-eclampsia | Soroka University Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT00990028 | Aug 2009 → Jul 2011 | brain injury | Autonomous University of San Luis Potosí | Completed | No outcome recorded |
| Phase 239 trials | ||||||
| Phase 2 | NCT07460960 | Mar 2026 → Dec 2027 expected | atherosclerosis, vasculogenic impotence | Lomonosov Moscow State University Medical Research and Educational Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07307989 | Aug 2025 → Jul 2029 expected | hyperlipidemia, ischemic stroke | Chang Gung Memorial Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06488105 | Aug 2024 → Nov 2027 expected | atherosclerosis, hyperlipidemia, lip disorder | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT05483010 | Feb 2024 → May 2027 expected | clonal hematopoiesis of indeterminate potential, myelodysplastic syndrome | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT05832229 | Dec 2023 → Aug 2029 expected | alcoholic liver cirrhosis, hepatitis C induced liver cirrhosis | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Recruiting | No outcome recorded |
| Phase 2 | NCT06102863 | Apr 2023 → Aug 2025 overdue | endometrial disorder | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05514938 | Nov 2022 → May 2025 | acute coronary syndrome, coronary artery disorder, lip disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT05895123 | Nov 2021 → Mar 2023 | ST-elevation myocardial infarction | Damanhour University | Completed | No outcome recorded |
| Phase 2 | NCT04824911 | Mar 2021 → Feb 2025 | stroke disorder | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04817904 | Nov 2020 → Aug 2021 | cisplatin toxicity | Cairo University | Unknown | No outcome recorded |
| Phase 2 | NCT04303806 | Oct 2020 → Oct 2022 | preeclampsia | Assiut University | Unknown | No outcome recorded |
| Phase 2 | NCT04491643 | Sep 2020 → Aug 2023 | endometrial carcinoma | Fudan University | Completed | No outcome recorded |
| Phase 2 | NCT04504851 | Aug 2020 → Mar 2021 | pulmonary tuberculosis | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 2 | NCT03532139 | Jul 2018 → Dec 2023 | ovarian cancer | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02901067 | Feb 2017 → May 2021 | venous thromboembolism | Denver Health and Hospital Authority | Terminated | No outcome recorded |
| Phase 2 | NCT02679664 | Nov 2016 → Jan 2020 | venous thromboembolism | Ottawa Hospital Research Institute | Unknown | No outcome recorded |
| Phase 2 | NCT02841774 | Nov 2016 → Jun 2021 | HIV infectious disease, coronary artery disorder | Matthew Feinstein | Completed | No outcome recorded |
| Phase 2 | NCT02569645 | Nov 2015 → Sep 2021 | rectal cancer | AHS Cancer Control Alberta | Completed | No outcome recorded |
| Phase 2 | NCT02516826 | Aug 2015 → Aug 2018 | coronary artery disorder | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT01837823 | Jul 2013 → Apr 2015 | coronary atherosclerosis, coronary stenosis | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT01863225 | May → Jun 2013 | coronary artery disorder, hyperlipidemia | Resverlogix Corp | Terminated | No outcome recorded |
| Phase 2 | NCT01524653 | Mar 2012 → Jul 2016 | neoplasm, venous thromboembolism | University of Vermont | Completed | No outcome recorded |
| Phase 2 | NCT01874743 | Mar 2012 → Sep 2013 | HIV infectious disease | Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba | Unknown | No outcome recorded |
| Phase 2 | NCT01105975 | Apr 2010 → Jun 2011 | hyperlipidemia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00929734 | Mar 2010 → Jan 2014 | chronic obstructive pulmonary disease | University Hospital, Akershus | Completed | No outcome recorded |
| Phase 2 | NCT01622777 | Feb 2010 → Jan 2011 | diabetic polyneuropathy | Alejandra Guillermina Miranda Diaz | Completed | No outcome recorded |
| Phase 2 | NCT01033955 | Jan → May 2010 | swine influenza | Canadian Critical Care Trials Group | Terminated | No outcome recorded |
| Phase 2 | NCT01798602 | Dec 2009 → May 2010 | swine influenza | Canadian Critical Care Trials Group | Terminated | No outcome recorded |
| Phase 2 | NCT00951132 | Sep 2009 → Dec 2012 | depressive disorder | University Hospital, Akershus | Withdrawn | No outcome recorded |
| Phase 2 | NCT00555230 | Jul 2007 → Dec 2009 | rheumatoid arthritis | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 2 | NCT00446940 | Dec 2006 → Mar 2007 | hepatitis C virus infection | Bader, Ted, M.D. | Completed | No outcome recorded |
| Phase 2 | NCT00364559 | Aug → Dec 2006 | intracerebral hemorrhage | Autonomous University of San Luis Potosí | Completed | No outcome recorded |
| Phase 2 | NCT00357123 | Aug 2006 → Jul 2011 | infectious disease with sepsis | Autonomous University of San Luis Potosí | Unknown | No outcome recorded |
| Phase 2 | NCT00315510 | Apr 2006 → Aug 2007 | ischemic disease | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00296400 | Feb 2006 → Jun 2009 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00296374 | Feb 2006 → Mar 2009 | diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00184951 | Apr 2004 → Jul 2005 | HIV infectious disease, hyperlipidemia | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00176332 | Mar 2004 → Dec 2006 | heart failure | University of Leipzig | Completed | No outcome recorded |
| Phase 2 | NCT00160745 | ? → Sep 2006 | hyperlipidemia | University of Erlangen-Nürnberg Medical School | Completed | No outcome recorded |
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT07313124 | Dec 2024 → Nov 2025 | cardiovascular disorder | Beni-Suef University | Completed | No outcome recorded |
| Phase 2/3 | NCT06834932 | Dec 2024 → Feb 2027 expected | hyperlipidemia | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04883840 | Oct 2020 → Oct 2025 | ulcerative colitis | Universitaire Ziekenhuizen KU Leuven | Terminated | No outcome recorded |
| Phase 2/3 | NCT04491682 | Sep 2020 → Jun 2022 | atypical endometrial hyperplasia | Fudan University | Completed | No outcome recorded |
| Phase 2/3 | NCT03521700 | Jun 2013 → Dec 2014 | renal artery obstruction | Chinese Academy of Medical Sciences, Fuwai Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT00986999 | Sep 2009 → Jan 2015 | HIV infectious disease, cardiovascular disorder | University of Hawaii | Terminated | No outcome recorded |
| Phase 395 trials | ||||||
| Phase 3 | NCT07232069 | Jul 2026 → Jul 2031 expected | atherosclerosis, coronary artery disorder | Duke University | Recruiting | No outcome recorded |
| Phase 3 | NCT07474649 | Jun 2026 → Jun 2028 expected | coronary atherosclerosis, hyperlipidemia, combined, 2, hyperlipoproteinemia | Daiichi Sankyo | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07012629 | Nov 2025 → Sep 2031 expected | MRI defined brain infarct | Aarhus University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07216482 | Nov 2025 → Dec 2026 expected | hyperlipidemia | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06646354 | Apr → May 2025 overdue | essential hypertension, hyperlipoproteinemia | Hyundai Pharm | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06772168 | Apr 2024 → Nov 2026 expected | hyperlipidemia, type 2 diabetes mellitus | CMG Pharmaceutical Co. Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT06698666 | Oct 2022 → Dec 2024 overdue | major depressive disorder | Ain Shams University | Recruiting | No outcome recorded |
| Phase 3 | NCT07564726 | Aug 2022 → Feb 2024 | essential hypertension, hyperlipoproteinemia | Celltrion Pharm, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05155137 | Dec 2021 → Dec 2029 expected | cognitive disorder, stroke disorder | Hospital Moinhos de Vento | Recruiting | No outcome recorded |
| Phase 3 | NCT04964544 | Jul 2021 → Mar 2023 | low density lipoprotein cholesterol, mild elevation of | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT04319627 | Feb 2021 → Jan 2028 expected | post-thrombotic syndrome, thrombotic disease, venous thromboembolism | Ottawa Hospital Research Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT04669041 | Dec 2020 → Jun 2022 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT04472611 | Oct 2020 → Mar 2022 | COVID-19 | Yale University | Completed | No outcome recorded |
| Phase 3 | NCT04659070 | Jul 2020 → May 2022 | essential hypertension, hyperlipoproteinemia | Hanlim Pharm. Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04737408 | May 2020 → Aug 2023 | coronary artery disorder | Bjarne Linde Noergaard | Unknown | No outcome recorded |
| Phase 3 | NCT04161001 | Nov 2019 → Nov 2021 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 3 | NCT02662894 | Oct 2019 → Sep 2020 | hyperlipidemia, hypertensive disorder | EMS | Withdrawn | No outcome recorded |
| Phase 3 | NCT03872232 | Feb 2019 → Aug 2020 | essential hypertension, hyperlipoproteinemia | Addpharma Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02850081 | Jun 2017 → Mar 2020 | carotid stenosis, stroke disorder | Columbia University | Terminated | No outcome recorded |
| Phase 3 | NCT03037372 | Jun 2017 → Jun 2022 | HIV infectious disease | Makerere University | Unknown | No outcome recorded |
| Phase 3 | NCT03103256 | May 2017 → Apr 2018 | hyperlipidemia | Yuhan Corporation | Completed | No outcome recorded |
| Phase 3 | NCT03067688 | Apr 2017 → Mar 2018 | hyperlipidemia, hypertensive disorder | Yuhan Corporation | Completed | No outcome recorded |
| Phase 3 | NCT03009487 | Jan 2017 → Apr 2018 | hyperlipidemia, hypertensive disorder | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 3 | NCT03210532 | Oct 2016 → Sep 2017 | hyperlipidemia, hypertensive disorder | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03088254 | Sep 2016 → Jul 2017 | — | Jeil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02741245 | Jun 2016 → Jan 2017 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT02748057 | May 2016 → Dec 2017 | familial hypercholesterolemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT02749994 | Apr 2016 → Feb 2017 | hyperlipidemia | IlDong Pharmaceutical Co Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02827903 | Jan 2016 → Nov 2017 | hyperlipidemia, type 2 diabetes mellitus | Jeil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02770261 | Dec 2015 → Aug 2016 | hyperlipidemia, hypertensive disorder | Alvogen Korea | Completed | No outcome recorded |
| Phase 3 | NCT03566316 | Nov 2015 → Jun 2017 | hyperlipidemia, combined, 2 | IlDong Pharmaceutical Co Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02546323 | Sep 2015 → Jan 2019 | atherosclerosis | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02434497 | Jun 2015 → Nov 2016 | homozygous familial hypercholesterolemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02546648 | Feb → Oct 2015 | atherosclerosis | McMaster University | Completed | No outcome recorded |
| Phase 3 | NCT02117453 | Oct 2014 → Nov 2019 | anti-neutrophil cytoplasmic antibody-associated vasculitis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT03288038 | Oct 2014 → Nov 2015 | hyperlipidemia | Shin Poong Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02551172 | Oct 2014 → Jan 2016 | hyperlipidemia | Hanmi Pharmaceutical Company Limited | Unknown | No outcome recorded |
| Phase 3 | NCT03571087 | Sep 2014 → Aug 2015 | hyperlipoproteinemia | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02899455 | Jul 2014 → Jun 2016 | hyperlipidemia, hypertensive disorder | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT02251847 | Jul 2014 → Jul 2015 | hyperlipidemia | IlDong Pharmaceutical Co Ltd | Unknown | No outcome recorded |
| Phase 3 | NCT02205606 | Jun 2014 → Feb 2015 | hyperlipidemia | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT02126358 | May 2014 → Mar 2016 | hyperlipidemia, type 2 diabetes mellitus | LG Life Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01914432 | Nov 2013 → Jun 2014 | hyperlipidemia, hypertensive disorder | Yuhan Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02087540 | May 2013 → Dec 2014 | hyperlipidemia, hypertensive disorder | IlDong Pharmaceutical Co Ltd | Unknown | No outcome recorded |
| Phase 3 | NCT01420549 | Mar 2013 → Nov 2014 | hyperlipidemia | Ache Laboratorios Farmaceuticos S.A. | Completed | No outcome recorded |
| Phase 3 | NCT01730053 | Nov 2012 → Apr 2014 | hyperlipidemia | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01918332 | Apr 2012 → Mar 2013 | hyperlipidemia, hypertensive disorder | LG Life Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01425398 | Nov 2011 → Dec 2013 | heart valve disorder | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| Phase 3 | NCT01164540 | Feb 2011 → Mar 2013 | pulmonary embolism, venous thromboembolism | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 3 | NCT01364220 | Aug 2010 → Apr 2013 | stroke disorder | Severance Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT02205775 | May 2010 → Mar 2012 | coronary artery disorder | G. d'Annunzio University | Terminated | No outcome recorded |
| Phase 3 | NCT01011478 | Mar 2010 → Dec 2014 | colorectal cancer, precancerous condition | NSABP Foundation Inc | Terminated | No outcome recorded |
| Phase 3 | NCT01007279 | Mar → Sep 2010 | myocardial infarction | University of Roma La Sapienza | Completed | No outcome recorded |
| Phase 3 | NCT01078675 | Feb 2010 → Feb 2013 | familial hypercholesterolemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00812955 | Nov 2008 → Jun 2009 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00783263 | Nov 2008 → May 2010 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00984932 | Sep 2008 → Jul 2009 | systemic sclerosis | University of Alexandria | Completed | No outcome recorded |
| Phase 3 | NCT00683618 | May 2008 → Jul 2009 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00620542 | Jan 2008 → Jun 2011 | coronary atherosclerosis | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00525824 | Aug 2007 → Sep 2008 | atherosclerosis, coronary artery disorder, hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00491530 | Jun 2007 → Nov 2008 | hyperlipidemia, combined, 2 | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00355615 | Jul 2006 → Jul 2008 | familial hypercholesterolemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00296387 | Jan 2006 → Oct 2007 | acute coronary syndrome | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00214604 | Feb 2005 → Feb 2007 | hyperlipoproteinemia type 3 | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00132717 | Jan 2005 → Jun 2007 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00115830 | Dec 2004 → Feb 2007 | atherosclerosis | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00090298 | Apr → Dec 2004 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00240305 | Apr 2004 → May 2006 | hyperlipidemia, metabolic syndrome X | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00228514 | Feb 2004 → Jul 2007 | heart failure, statin toxicity | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00214630 | Dec 2003 → Aug 2007 | acute coronary syndrome | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00329173 | Nov 2003 → Aug 2004 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00206310 | Sep 2003 → Jul 2007 | heart failure | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00240266 | Aug 2003 → Nov 2004 | hyperlipidemia, metabolic syndrome X | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00241488 | Jun 2003 → Dec 2005 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00239330 | Jun 2003 → Feb 2005 | hyperlipoproteinemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00653965 | May 2003 → Feb 2005 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00653588 | Apr 2003 → Sep 2004 | coronary artery disorder, hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00240292 | Feb 2003 → ? | congestive heart failure | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00239681 | Feb 2003 → Sep 2008 | combined low LDL and fibrinogen | AstraZeneca | Terminated | No outcome recorded |
| Phase 3 | NCT00240279 | Jan 2003 → Oct 2008 | hyperlipoproteinemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00240331 | Jan 2003 → Oct 2008 | end stage renal failure | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00240318 | Nov 2002 → Nov 2005 | coronary atherosclerosis | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00654225 | Oct 2002 → Mar 2005 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00654446 | Sep 2002 → Apr 2004 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00336336 | Aug 2002 → Apr 2008 | heart failure | Gruppo di Ricerca GISSI | Completed | No outcome recorded |
| Phase 3 | NCT00225589 | Aug 2002 → May 2006 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00654173 | Jun 2002 → Sep 2004 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00654485 | May 2002 → Feb 2005 | metabolic syndrome X | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00653744 | Mar 2002 → Mar 2004 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00654602 | Feb 2002 → Nov 2004 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00657527 | Dec 2001 → Dec 2002 | coronary artery disorder, myocardial ischemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00654407 | Nov 2001 → Sep 2004 | hyperlipoproteinemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00654537 | Apr 2001 → Oct 2004 | familial hypercholesterolemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00654394 | Jan 2000 → Aug 2004 | carotid stenosis, hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00654303 | Aug 1999 → Feb 2005 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 4113 trials | ||||||
| Phase 4 | NCT07303816 | Jun 2026 → Mar 2031 expected | cancer, venous thromboembolism | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06767774 | Apr 2025 → Aug 2029 expected | atherosclerotic cardiovascular disease, diabetes mellitus | Korea University Anam Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06820086 | Mar 2025 → Mar 2031 expected | — | Mikk JÜRISSON | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06856772 | Feb 2025 → Mar 2028 expected | atherosclerotic cardiovascular disease | Tor Biering-Sørensen | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06785727 | Feb 2025 → Dec 2028 expected | transient ischemic attack | Prof. dr. Nathalie van der Velde | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06804980 | Feb 2025 → Dec 2026 expected | statin toxicity | Minneapolis Heart Institute Foundation | Recruiting | No outcome recorded |
| Phase 4 | NCT06765265 | Jan 2025 → Jan 2026 overdue | acute coronary syndrome | King Edward Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT05613426 | Apr 2023 → Jul 2025 | ST-elevation myocardial infarction | Henan Institute of Cardiovascular Epidemiology | Terminated | No outcome recorded |
| Phase 4 | NCT05742841 | Mar → Jun 2023 | lip disorder | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT06273215 | Mar 2023 → Dec 2025 | diabetes mellitus | Peking University Third Hospital | Unknown | No outcome recorded |
| Show all 113 trials opens the full record — a long page | ||||||
| Phase not applicable27 trials | ||||||
| — | NCT07704918 | Dec 2026 → Dec 2027 expected | melanoma | University of Colorado, Denver | Not yet recruiting | No outcome recorded |
| — | NCT07679828 | Jul 2026 → Dec 2029 expected | diabetes mellitus, hyperlipidemia, hypertensive disorder | China Medical University, China | Not yet recruiting | No outcome recorded |
| — | NCT07401017 | Mar → Aug 2026 overdue | hyperlipidemia, statin toxicity | Taipei Medical University WanFang Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07432516 | Feb 2026 → Jun 2033 expected | coronary artery disorder | Yonsei University | Not yet recruiting | No outcome recorded |
| — | NCT06603363 | May 2025 → Oct 2026 expected | coronary atherosclerosis, hyperlipidemia | Prof. Maurovich-Horvat Pál | Recruiting | No outcome recorded |
| — | NCT06231966 | Apr 2024 → May 2026 overdue | peripheral arterial disease | Yonsei University | Recruiting | No outcome recorded |
| — | NCT05741372 | Sep 2023 → Dec 2024 | cirrhosis of liver | Boehringer Ingelheim | Completed | No outcome recorded |
| — | NCT04176978 | Apr 2021 → Dec 2022 | atherosclerosis, psoriatic arthritis | Chinese University of Hong Kong | Withdrawn | No outcome recorded |
| — | NCT04699279 | Jan 2021 → Dec 2024 overdue | aortic disorder | Nanjing Medical University | Recruiting | No outcome recorded |
| — | NCT05368545 | May 2020 → Apr 2024 | coronary artery disorder | Aarhus University Hospital | Completed | No outcome recorded |
| — | NCT04923152 | Jan 2020 → Jan 2021 | — | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| — | NCT03907423 | Apr 2019 → Jan 2021 | type 2 diabetes mellitus | Rehab Werida | Completed | No outcome recorded |
| — | NCT06094244 | Mar 2017 → Dec 2020 | intracerebral hemorrhage | Pomeranian Medical University Szczecin | Completed | No outcome recorded |
| — | NCT02785874 | Sep → Oct 2016 | hepatocellular carcinoma | Taipei Medical University WanFang Hospital | Terminated | No outcome recorded |
| — | NCT02420899 | Apr 2015 → Jul 2016 | acute coronary syndrome | Beijing Friendship Hospital | Unknown | No outcome recorded |
| — | NCT02341794 | Jan 2015 → Dec 2017 | intracranial arterial disease | Tokyo Medical University | Unknown | No outcome recorded |
| — | NCT01982461 | Nov 2013 → Jan 2014 | hyperlipoproteinemia | Pin Siang Medical Biotechnology Co., Ltd. | Unknown | No outcome recorded |
| — | NCT02305862 | Jan 2013 → Dec 2016 | arteriosclerosis disorder, diabetes mellitus, lip disorder | Capital Medical University | Unknown | No outcome recorded |
| — | NCT01389388 | Jan → Aug 2013 | ankylosing spondylitis, arterial disorder | Diakonhjemmet Hospital | Completed | No outcome recorded |
| — | NCT01613794 | Dec 2012 → Dec 2016 | pulmonary embolism, venous thromboembolism | Leiden University Medical Center | Completed | No outcome recorded |
| — | NCT01634906 | Jul 2012 → Mar 2013 | atherosclerosis, hyperlipidemia | Sint Franciscus Gasthuis | Completed | No outcome recorded |
| — | NCT01544309 | Mar 2012 → Jun 2014 | hyperlipidemia | Listen Trial Group | Completed | No outcome recorded |
| — | NCT01259791 | Sep 2010 → Aug 2013 | statin toxicity | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| — | NCT00970606 | Oct 2009 → Jul 2011 | acute respiratory distress syndrome, swine influenza | Gordon Bernard | Terminated | No outcome recorded |
| — | NCT00554138 | Nov 2007 → Mar 2008 | — | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT00464503 | Sep → Oct 2007 | statin toxicity | University of Antwerp | Completed | No outcome recorded |
| — | NCT00371579 | Oct 2006 → Oct 2007 | hepatitis C virus infection | UMC Utrecht | Withdrawn | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT00934258 | — | hyperlipidemia | National Taiwan University Hospital | Available | No outcome recorded |
| — | NCT00965315 | — | cardiovascular disorder | National Taiwan University Hospital | Available | No outcome recorded |
Also used as a comparator or background therapy in 239 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06105060 Comparator | Dec 2023 → Jun 2024 | metabolic dysfunction-associated steatohepatitis | Beni-Suef University | Completed | No outcome recorded |
| Phase 0 | NCT00783042 Comparator | Oct 2008 → May 2009 | atherosclerosis, coronary artery disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 123 trials | ||||||
| Phase 1 | NCT07629999 Background | Jun 2026 → Jun 2027 expected | — | Bristol-Myers Squibb | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07001787 Comparator | Jun 2025 → Feb 2026 overdue | hyperlipidemia | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06899061 Comparator | Mar 2025 → Feb 2026 overdue | high grade malignant neoplasm | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06742853 Background | Dec 2024 → Oct 2025 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06304896 Comparator | May 2024 → May 2025 | chemotherapy-induced toxicity | Arab Contractors Medical Centre | Unknown | No outcome recorded |
| Phase 1 | NCT05384262 Comparator | May 2022 → Jun 2024 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05373277 Comparator | May → Dec 2022 | — | Helsinki University Central Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT03753477 Comparator | Dec 2017 → Jan 2018 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT04895059 Comparator | Apr 2017 → Jan 2018 | — | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT02608242 Comparator | Nov 2015 → Jun 2016 | hyperlipidemia, hypertensive disorder | Yuhan Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT03009474 Comparator | Feb → Apr 2015 | hyperlipidemia, hypertensive disorder | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02289430 Comparator | Dec 2014 → Feb 2015 | — | NVP Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT02029625 Comparator | Feb → Mar 2014 | hyperlipidemia | NVP Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT02026817 Comparator | Dec 2013 | diabetes mellitus | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT02011633 Comparator | Oct → Nov 2013 | diabetes mellitus | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT01929512 Comparator | Jun → Aug 2013 | diabetes mellitus | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT01493856 Comparator | Jan → Feb 2012 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT01411111 Comparator | Jan → Feb 2011 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01146483 Comparator | Apr 2010 → Dec 2011 | — | University of Montreal Hospital Centre (CHUM) | Completed | No outcome recorded |
| Phase 1 | NCT00808678 Comparator | Dec 2008 → Jan 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00826358 Comparator | Nov 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00728780 Comparator | Aug → Sep 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00681395 Comparator | May → Aug 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06048588 Comparator | Oct 2023 → Apr 2025 | atherosclerotic cardiovascular disease | Beijing Inno Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT04434365 Background | Jun → Nov 2019 | coronary artery disorder | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT00885495 Comparator | Jan 2009 → Apr 2010 | HIV infectious disease | University of Cincinnati | Completed | No outcome recorded |
| Phase 222 trials | ||||||
| Phase 2 | NCT07032389 Background | Dec 2025 → Jun 2030 expected | acute coronary syndrome | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07218900 Background | Nov 2025 → Sep 2026 expected | hyperlipidemia | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06924684 Comparator | Dec 2024 → Jun 2025 overdue | ST-elevation myocardial infarction | Sheikh Zayed Federal Postgraduate Medical Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04846231 Comparator | Apr 2021 → Jul 2022 | hyperlipidemia | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 2 | NCT03113994 Comparator | Feb 2018 → Dec 2022 | metabolic syndrome X, osteoporosis, spinal cord injury | Dr. B. Catharine. Craven | Terminated | No outcome recorded |
| Phase 2 | NCT02977065 Comparator | Mar → Dec 2017 | hyperlipidemia | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 2 | NCT02072161 Background | Mar 2014 → Jan 2015 | hyperlipidemia | Esperion Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01972178 Background | Nov 2013 → Jul 2014 | hyperlipidemia | Pronova BioPharma | Terminated | No outcome recorded |
| Phase 2 | NCT01970215 Comparator | Aug 2013 → Jul 2014 | hyperlipidemia | Xention Ltd | Completed | No outcome recorded |
| Phase 2 | NCT01890967 Background | Jun 2013 → Apr 2014 | hyperlipoproteinemia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01863914 Comparator | Nov 2012 → Dec 2018 | diabetes mellitus, end stage renal failure | National Cheng-Kung University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02129231 Comparator | Feb 2012 → Jan 2014 | diabetic polyneuropathy, disorder of defective peroxisome oxidative status | University of Guadalajara | Completed | No outcome recorded |
| Phase 2 | NCT01455935 Comparator | Nov 2011 → Dec 2013 | stroke disorder | Jacobs Neurological Institute | Unknown | No outcome recorded |
| Phase 2 | NCT01526460 Comparator | Aug 2011 → Feb 2014 | platelet disorder, undefined | IRCCS San Raffaele | Completed | No outcome recorded |
| Phase 2 | NCT01342211 Background | Jul 2011 → Feb 2012 | hyperlipidemia | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT01218802 Comparator | Feb 2011 → May 2014 | HIV infectious disease, cardiovascular disorder | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01299038 Comparator | Oct 2010 → Nov 2013 | female breast carcinoma | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01170585 Comparator | Jul 2010 → May 2014 | atherosclerosis, systemic lupus erythematosus | Imperial College London | Completed | No outcome recorded |
| Phase 2 | NCT01923077 Comparator | Apr 2010 → Sep 2013 | acute myocardial infarction | Svendborg Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT00978419 Comparator | Mar 2010 → Feb 2011 | — | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00329758 Comparator | Jul 2006 → Oct 2007 | brain injury | Autonomous University of San Luis Potosí | Completed | No outcome recorded |
| Phase 2 | NCT00693589 Comparator | Jan 2005 → Feb 2007 | cardiovascular disorder | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 2/315 trials | ||||||
| Phase 2/3 | NCT06975111 Comparator | Mar 2026 → Oct 2029 expected | cardiovascular disorder | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07504198 Comparator | Mar 2026 → Apr 2027 expected | peripheral neuropathy | Tanta University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06696820 Comparator | Nov 2024 → Mar 2026 | ischemic stroke | Xiang Luo | Completed | No outcome recorded |
| Phase 2/3 | NCT04359095 Comparator | Aug 2020 → Mar 2021 | COVID-19 | National University of Colombia | Completed | No outcome recorded |
| Phase 2/3 | NCT05565976 Background | Aug 2020 → Dec 2024 | cognitive impairment with or without cerebellar ataxia, ischemic stroke, metabolic syndrome X, vascular dementia | Jaime Daniel Mondragon | Unknown | No outcome recorded |
| Phase 2/3 | NCT03610321 Background | Sep 2019 → Sep 2021 | coronary artery disorder | First Affiliated Hospital of Harbin Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03720067 Comparator | Jan 2019 → Dec 2020 | cirrhosis of liver, esophageal varices with bleeding, portal hypertension | Federal University of Rio de Janeiro | Unknown | No outcome recorded |
| Phase 2/3 | NCT02979704 Comparator | Sep 2016 → Jun 2017 | hyperlipidemia | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Unknown | No outcome recorded |
| Phase 2/3 | NCT03204058 Comparator | Feb 2016 → Feb 2017 | chronic periodontitis | Government Dental College and Research Institute, Bangalore | Completed | No outcome recorded |
| Phase 2/3 | NCT02985099 Comparator | Nov 2015 → Jul 2016 | chronic periodontitis, type 2 diabetes mellitus | Government Dental College and Research Institute, Bangalore | Completed | No outcome recorded |
| Phase 2/3 | NCT03043196 Comparator | Jun 2015 → Apr 2016 | chronic periodontitis | Government Dental College and Research Institute, Bangalore | Completed | No outcome recorded |
| Phase 2/3 | NCT02800902 Comparator | May 2015 → Feb 2016 | chronic periodontitis | Government Dental College and Research Institute, Bangalore | Completed | No outcome recorded |
| Phase 2/3 | NCT02600520 Comparator | Nov 2014 → May 2015 | chronic periodontitis | Government Dental College and Research Institute, Bangalore | Completed | No outcome recorded |
| Phase 2/3 | NCT02283515 Comparator | Jan → Jun 2014 | chronic periodontitis | Government Dental College and Research Institute, Bangalore | Completed | No outcome recorded |
| Phase 2/3 | NCT00679510 Comparator | Feb 2004 → Jan 2008 | rheumatoid arthritis | University of Dundee | Completed | No outcome recorded |
| Phase 372 trials | ||||||
| Phase 3 | NCT07586540 Background | Jul 2027 → Mar 2030 expected | carotid stenosis | Middle East North Africa Stroke and Interventional Neurotherapies Organization | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07619118 Comparator | Sep 2026 → May 2027 expected | hyperlipidemia | AstraZeneca | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07619131 Comparator | Aug 2026 → Jul 2027 expected | hyperlipidemia | AstraZeneca | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07239414 Comparator | Nov 2025 → Nov 2026 expected | cardiovascular disorder | Sohaib Ashraf | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06317051 Comparator | Dec 2024 → Jul 2026 overdue | HIV infectious disease | Kirby Institute | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06360120 Comparator | Apr 2024 → Sep 2025 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT06358313 Comparator | Apr 2024 → May 2026 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT04968509 Background | Mar 2024 → Dec 2027 expected | aortic valve stenosis | Beijing Anzhen Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT04602754 Comparator | Dec 2023 → May 2026 overdue | type 2 diabetes mellitus | EMS | Recruiting | No outcome recorded |
| Phase 3 | NCT05731596 Comparator | Jun 2023 → Feb 2024 | metabolic dysfunction-associated steatohepatitis | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT04603508 Comparator | Mar 2023 → Apr 2025 | hyperlipidemia, type 2 diabetes mellitus | EMS | Unknown | No outcome recorded |
| Phase 3 | NCT03540355 Comparator | Mar 2021 → Jan 2025 | hyperlipidemia | EMS | Completed | No outcome recorded |
| Phase 3 | NCT03527069 Comparator | Jan 2021 → Aug 2024 | hyperlipidemia, hypertriglyceridemia | EMS | Completed | No outcome recorded |
| Phase 3 | NCT05338723 Comparator | Sep 2020 → Sep 2023 | breast cancer, chemotherapy-induced toxicity | Tanta University | Completed | No outcome recorded |
| Phase 3 | NCT04074551 Comparator | Jul 2019 → Mar 2020 | hyperlipidemia, hypertensive disorder | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT07600385 Comparator | Mar 2019 → May 2022 | peripheral arterial disease | Korea United Pharm. Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03510715 Background | Aug 2018 → Feb 2020 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT03510884 Background | May 2018 → Jan 2021 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT03415178 Background | Mar → Aug 2018 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT03016819 Comparator | Aug 2017 → Dec 2027 expected | alveolar soft part sarcoma, leiomyosarcoma, synovial sarcoma | Advenchen Laboratories, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT03156842 Comparator | May 2017 → Dec 2018 | essential hypertension, hyperlipidemia | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT03536598 Comparator | Oct 2016 → Sep 2017 | hyperlipidemia, combined, 2 | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02715726 Background | Jul 2016 → Aug 2018 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02586129 Comparator | Nov 2015 → Jul 2017 | hyperlipidemia, type 2 diabetes mellitus | Yuhan Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02586155 Background | Nov 2015 → Nov 2020 | coronary artery disorder, type 2 diabetes mellitus | Resverlogix Corp | Completed | No outcome recorded |
| Phase 3 | NCT02476006 Background | Jun 2015 → Apr 2019 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02289963 Comparator | Jan 2015 → Apr 2016 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02390375 Comparator | Nov 2014 → Apr 2016 | hyperlipidemia | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02226198 Comparator | Nov 2014 → Jul 2015 | homozygous familial hypercholesterolemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02262143 Background | Nov 2014 → Oct 2016 | hyperlipidemia, combined, 2 | IlDong Pharmaceutical Co Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02166814 Comparator | Aug 2014 → Sep 2015 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02445352 Comparator | Jul 2014 → Jan 2015 | hyperlipoproteinemia | Alvogen Korea | Completed | No outcome recorded |
| Phase 3 | NCT03026933 Comparator | May 2014 → Mar 2016 | hyperlipidemia | Kuhnil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02107898 Background | Mar 2014 → Jan 2015 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01954394 Background | Dec 2013 → Jun 2017 | familial hypercholesterolemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01926782 Background | Sep 2013 → Sep 2014 | hyperlipoproteinemia | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01763866 Background | Jan → Nov 2013 | hyperlipidemia | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01709500 Background | Dec 2012 → May 2014 | familial hypercholesterolemia | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01663402 Background | Oct 2012 → Jan 2018 | atherosclerotic cardiovascular disease | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01730040 Comparator | Oct 2012 → Apr 2014 | hyperlipidemia | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01764295 Comparator | Sep 2012 → May 2013 | hyperlipidemia, hypertensive disorder | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 3 | NCT01644188 Background | Aug 2012 → May 2014 | hyperlipoproteinemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01644175 Background | Jul 2012 → Apr 2014 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01623115 Background | Jul 2012 → Apr 2014 | familial hypercholesterolemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01617655 Background | Jun 2012 → May 2014 | familial hypercholesterolemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01624857 Comparator | Jun 2012 → Dec 2013 | coronary artery disorder | China National Center for Cardiovascular Diseases | Unknown | No outcome recorded |
| Phase 3 | NCT01507831 Background | Jan 2012 → Nov 2014 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01494090 Comparator | Aug 2011 → Mar 2012 | bone disorder | University Hospital, Brest | Terminated | No outcome recorded |
| Phase 3 | NCT01228227 Comparator | Oct 2010 → Apr 2011 | acute myocardial infarction | Gennaro Sardella | Completed | No outcome recorded |
| Phase 3 | NCT01154036 Comparator | Jul 2010 → Sep 2012 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT01378715 Comparator | Jun 2010 → Jun 2012 | coronary artery disorder | University Hospital, Motol | Unknown | No outcome recorded |
| Phase 3 | NCT00979121 Comparator | Jan 2010 → Nov 2013 | acute lung injury, infectious disease with sepsis | National Heart, Lung, and Blood Institute (NHLBI) | Terminated | No outcome recorded |
| Phase 3 | NCT00862251 Comparator | Apr 2009 → Mar 2011 | cardiovascular disorder, diabetes mellitus | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00854503 Comparator | Sep 2008 → Mar 2010 | hypertriglyceridemia 2, type 2 diabetes mellitus | University of Rome Tor Vergata | Completed | No outcome recorded |
| Phase 3 | NCT00680017 Comparator | Jun 2008 → Apr 2011 | chronic kidney disease, hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01936805 Comparator | Jan 2008 → Jan 2012 | atherosclerosis | Yuksek Ihtisas Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00664469 Comparator | Aug 2007 → Mar 2010 | hyperlipidemia | Sunnybrook Health Sciences Centre | Terminated | No outcome recorded |
| Phase 3 | NCT00505154 Comparator | Jul 2007 → Jul 2013 | dilated cardiomyopathy | Oslo University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00532311 Comparator | Jul 2007 → Apr 2008 | hyperlipidemia | Takeda | Terminated | No outcome recorded |
| Phase 3 | NCT00463606 Comparator | Apr 2007 → Feb 2008 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00462748 Comparator | Mar 2007 → Jun 2008 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00479713 Comparator | Feb 2007 → Mar 2008 | hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00300430 Comparator | Sep 2006 → Mar 2008 | coronary artery disorder, hyperlipidemia, combined, 2 | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT01068626 Comparator | May 2006 → Oct 2008 | abdominal obesity-metabolic syndrome | Göteborg University | Completed | No outcome recorded |
| Phase 3 | NCT00300482 Comparator | Mar → Dec 2006 | coronary artery disorder, hyperlipidemia, combined, 2 | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00249899 Background | Nov 2005 → Mar 2007 | hyperlipoproteinemia | Takeda | Terminated | No outcome recorded |
| Phase 3 | NCT00249912 Comparator | Oct 2005 → Apr 2007 | hyperlipoproteinemia | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00251680 Comparator | Oct 2005 → May 2007 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00653445 Background | Jun 2004 → Jun 2005 | atherosclerosis, coronary artery disorder, hyperlipoproteinemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00127218 Background | Sep 2003 → Dec 2008 | atherosclerosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 3 | NCT00800800 Comparator | Nov 2002 → Sep 2008 | aortic valve stenosis | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00379249 Background | Feb 2002 → Feb 2004 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 471 trials | ||||||
| Phase 4 | NCT07605130 Background | May 2026 → Sep 2028 expected | cognitive disorder, intracranial arteriosclerosis | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07254221 Comparator | Feb 2026 → Apr 2028 expected | breast cancer, chemotherapy-induced toxicity | Shiraz University of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07255820 Comparator | Jan → Mar 2026 overdue | hyperlipoproteinemia, type 2 diabetes mellitus | Bahria University | Recruiting | No outcome recorded |
| Phase 4 | NCT06902740 Comparator | Nov 2025 → Dec 2027 expected | cerebral artery stenosis, cerebral atherosclerosis | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06767345 Comparator | May 2025 → Jan 2028 expected | coronary atherosclerosis | Korea University Anam Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06338293 Background | Mar 2024 → Jun 2025 overdue | coronary artery disorder | Nanjing First Hospital, Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT06186037 Comparator | Feb 2024 → Feb 2029 expected | coronary artery disorder, hyperlipidemia | Saint Vincent's Hospital, Korea | Recruiting | No outcome recorded |
| Phase 4 | NCT05850091 Comparator | Dec 2023 → Jun 2027 expected | coronary artery disorder | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06153433 Comparator | Nov 2023 → Jul 2024 | hyperlipidemia | Yonsei University | Unknown | No outcome recorded |
| Phase 4 | NCT05845424 Comparator | Jul 2023 → Jun 2029 expected | coronary artery disorder, hyperlipidemia, metabolic syndrome X | Samsung Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT05910476 Comparator | May 2023 → Sep 2026 expected | coronary artery disorder, hyperlipidemia | Yonsei University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05579626 Comparator | Mar 2023 → Dec 2030 expected | atherosclerotic cardiovascular disease, prediabetes syndrome | Seung-Whan Lee, M.D., Ph.D. | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05661552 Background | Dec 2022 → Feb 2025 | hyperlipoproteinemia | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT05585151 Comparator | Nov 2022 → Apr 2024 | cerebral atherosclerosis | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 4 | NCT05884502 Comparator | Sep 2022 → Dec 2023 | hyperlipidemia, ischemic stroke | Korea University Anam Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05298475 Background | Apr 2022 → Apr 2023 | acute coronary syndrome | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT04499859 Comparator | Oct 2020 → Aug 2026 overdue | myocardial infarction, statin toxicity | Kiyuk Chang, MD,PhD | Recruiting | No outcome recorded |
| Phase 4 | NCT03770312 Comparator | Mar 2020 → Jan 2026 overdue | combined low LDL and fibrinogen | Yonsei University | Recruiting | No outcome recorded |
| Phase 4 | NCT04700436 Comparator | Jan 2020 → May 2021 | hyperlipidemia, type 2 diabetes mellitus | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05072054 Comparator | Oct 2019 → Jun 2022 | symptomatic heart failure | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 4 | NCT03993236 Comparator | Sep 2019 → Sep 2021 | ischemic stroke | Keun-Sik Hong | Completed | No outcome recorded |
| Phase 4 | NCT03860220 Comparator | Apr 2019 → Sep 2023 | hyperlipidemia, hypertensive disorder | Hyo-Soo Kim | Completed | No outcome recorded |
| Phase 4 | NCT04851769 Background | Mar 2019 → Jan 2021 | — | Beijing Anzhen Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03657758 Comparator | Sep 2018 → Aug 2020 | coronary artery disorder | Kobe University | Unknown | No outcome recorded |
| Phase 4 | NCT03474562 Background | Apr 2018 → Jun 2019 | atherosclerotic cardiovascular disease, hypertensive disorder, prediabetes syndrome | Yuhan Corporation | Completed | No outcome recorded |
| Phase 4 | NCT03529253 Comparator | Apr 2018 → Sep 2020 | coronary artery disorder | Kobe University | Unknown | No outcome recorded |
| Phase 4 | NCT03552432 Background | Aug 2017 → Sep 2020 | coronary artery disorder | Kobe University | Unknown | No outcome recorded |
| Phase 4 | NCT03169985 Comparator | Jul 2017 → Jan 2027 expected | coronary artery disorder | Samsung Medical Center | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04056169 Comparator | Jun 2017 → Jul 2019 | acute coronary syndrome, arterial disorder | Yuhan Corporation | Completed | No outcome recorded |
| Phase 4 | NCT03255044 Comparator | Jun 2017 → Mar 2019 | heart failure | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT02984982 Background | Nov 2016 → Jul 2018 | acute coronary syndrome, hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT02968160 Comparator | Oct 2016 → Feb 2018 | metabolic syndrome X | Yuhan Corporation | Terminated | No outcome recorded |
| Phase 4 | NCT02579499 Comparator | Sep 2016 → Nov 2022 | coronary artery disorder | Yonsei University | Unknown | No outcome recorded |
| Phase 4 | NCT03074630 Background | May 2016 → Apr 2018 | hyperlipidemia, type 2 diabetes mellitus | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| Phase 4 | NCT02772640 Comparator | Mar 2016 → Jan 2019 | hyperlipidemia | Collegium Medicum w Bydgoszczy | Completed | No outcome recorded |
| Phase 4 | NCT03949374 Comparator | Oct 2015 → Apr 2018 | hyperlipidemia | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT02767401 Comparator | Sep 2015 → Aug 2018 | arterial occlusion, myocardial stunning | The First Affiliated Hospital of Dalian Medical University | Completed | No outcome recorded |
| Phase 4 | NCT02428374 Comparator | May 2015 → Apr 2018 | — | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT02030054 Comparator | Jan → Jun 2015 | coronary artery disorder | University of Roma La Sapienza | Unknown | No outcome recorded |
| Phase 4 | NCT02234492 Comparator | Sep 2014 → Oct 2018 | HIV infectious disease, cardiovascular disorder | Ottawa Heart Institute Research Corporation | Completed | No outcome recorded |
| Phase 4 | NCT01899027 Comparator | Jan 2014 → Dec 2016 | hypertensive disorder | University of Roma La Sapienza | Unknown | No outcome recorded |
| Phase 4 | NCT02232360 Comparator | Jan 2014 → Dec 2020 | coronary artery disorder | Gachon University Gil Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT01870804 Comparator | May 2013 → Jul 2016 | acute coronary syndrome | Centro Cardiopatici Toscani | Completed | No outcome recorded |
| Phase 4 | NCT03011775 Background | Nov 2012 → Jun 2014 | coronary atherosclerosis, metabolic syndrome X | Ukrainian Medical Stomatological Academy | Completed | No outcome recorded |
| Phase 4 | NCT01697735 Comparator | Sep 2012 → Sep 2015 | hyperlipidemia | Wenzhou Medical University | Terminated | No outcome recorded |
| Phase 4 | NCT01613729 Comparator | Jul 2012 → Jul 2013 | hyperlipidemia | D16 Pharma & Biotec Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT01582165 Comparator | Jun 2012 → Jun 2016 | intermediate coronary syndrome | Oslo University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01567774 Comparator | Apr 2012 → Mar 2014 | coronary artery disorder | University of Roma La Sapienza | Unknown | No outcome recorded |
| Phase 4 | NCT01646307 Comparator | Jan 2012 → Jan 2013 | — | Beijing Anzhen Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01660191 Comparator | Dec 2011 → Aug 2013 | hyperlipidemia | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01660919 Comparator | Oct 2011 → Jan 2013 | hyperlipoproteinemia | Gachon University Gil Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01325818 Comparator | Mar 2011 | coronary artery disorder, hyperlipoproteinemia | Yokohama City University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT01185938 Comparator | Jul 2010 → Sep 2012 | acute coronary syndrome | Centro Cardiopatici Toscani | Completed | No outcome recorded |
| Phase 4 | NCT01699126 Comparator | May 2010 → Feb 2013 | obstructive sleep apnea syndrome | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01023607 Comparator | Dec 2009 → Aug 2013 | coronary atherosclerosis, hyperlipidemia | Harbin Medical University | Completed | No outcome recorded |
| Phase 4 | NCT01010516 Comparator | Oct 2009 → Dec 2011 | hyperlipidemia | University of Ioannina | Unknown | No outcome recorded |
| Phase 4 | NCT00913562 Comparator | Jun 2009 → Nov 2014 | diabetes mellitus, glaucoma | Medical University of Vienna | Withdrawn | No outcome recorded |
| Phase 4 | NCT00871351 Comparator | Feb 2009 → May 2010 | hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00850460 Comparator | Feb 2009 → Feb 2013 | statin toxicity | Rockefeller University | Terminated | No outcome recorded |
| Phase 4 | NCT02305355 Background | Feb 2009 → Feb 2011 | hypertriglyceridemia, type 2 diabetes mellitus | Kuhnil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT00923676 Comparator | Apr 2008 → Oct 2015 | hyperlipidemia, sexual disorder | University of Campania Luigi Vanvitelli | Unknown | No outcome recorded |
| Phase 4 | NCT01245894 Comparator | Nov 2007 → Jun 2009 | myocardial infarction | Odense University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01223625 Comparator | Nov 2007 → Jun 2009 | atherosclerosis | Odense University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01203982 Comparator | Nov 2007 → Jun 2009 | ST-elevation myocardial infarction, arterial disorder | Odense University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00631189 Comparator | Oct 2007 → Oct 2008 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00457652 Comparator | Jun → Sep 2007 | ischemic disease | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00468923 Comparator | May 2007 → Dec 2015 | stroke disorder | Population Health Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT00427960 Comparator | Dec 2006 → Feb 2008 | hyperlipidemia | AstraZeneca | Terminated | No outcome recorded |
| Phase 4 | NCT00506961 Comparator | Jun 2006 → Jul 2007 | hyperlipidemia, type 2 diabetes mellitus | Taipei Veterans General Hospital, Taiwan | Completed | No outcome recorded |
| Phase 4 | NCT00371501 Comparator | Jun 2006 → Dec 2009 | atherosclerosis, systemic lupus erythematosus, thrombotic disease | Tuen Mun Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00665834 Comparator | Apr 2006 → Sep 2007 | acute coronary syndrome, hyperlipidemia | Queen's University | Completed | No outcome recorded |
| Phase not applicable31 trials | ||||||
| — | NCT07699003 Background | Aug 2026 → Aug 2029 expected | cerebral artery occlusion | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| — | NCT07626840 Comparator | Jun 2026 → Jun 2028 expected | acute coronary syndrome | Samsung Medical Center | Not yet recruiting | No outcome recorded |
| — | NCT07568574 Background | Mar 2026 → May 2028 expected | — | Enhanced Emirates Limited | Enrolling by invitation | No outcome recorded |
| — | NCT07359105 Comparator | Mar 2026 → Dec 2029 expected | type 2 diabetes mellitus | Sin Gon Kim | Recruiting | No outcome recorded |
| — | NCT06791031 Background | Jan 2026 → Dec 2027 expected | coronary atherosclerosis | West China Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06896708 Background | Aug 2025 → Jul 2027 expected | coronary atherosclerosis | Liu yong | Recruiting | No outcome recorded |
| — | NCT06782243 Comparator | Dec 2024 → Jul 2025 | acute coronary syndrome | Khyber Medical University Peshawar | Completed | No outcome recorded |
| — | NCT06910098 Comparator | Dec 2023 → Jun 2024 | hypercholesterolemia, familial, 1 | Central Park Medical College | Completed | No outcome recorded |
| — | NCT06096909 Background | Nov 2023 → Nov 2025 overdue | acute coronary syndrome | China National Center for Cardiovascular Diseases | Not yet recruiting | No outcome recorded |
| — | NCT06515652 Comparator | Sep 2023 → Jul 2024 overdue | metabolic syndrome X | Hamdard University | Recruiting | No outcome recorded |
| — | NCT05457582 Comparator | Mar 2023 → Sep 2026 expected | acute coronary syndrome, hyperlipidemia | Nanjing First Hospital, Nanjing Medical University | Recruiting | No outcome recorded |
| — | NCT05624658 Background | Sep 2022 → May 2024 | hyperlipidemia | Samara Regional Cardiology Dispensary | Unknown | No outcome recorded |
| — | NCT05397405 Background | May 2022 → May 2026 overdue | cerebral artery stenosis | Nanjing First Hospital, Nanjing Medical University | Recruiting | No outcome recorded |
| — | NCT04974814 Comparator | May 2021 → Oct 2022 | ST-elevation myocardial infarction | Beni-Suef University | Unknown | No outcome recorded |
| — | NCT04581759 Background | Apr 2021 → Apr 2023 | ischemic stroke | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| — | NCT07074834 Background | Feb 2021 → Sep 2022 | coronary artery disorder | Shiyan City Renmin Hospital | Completed | No outcome recorded |
| — | NCT04744571 Background | Feb 2021 → Dec 2022 | arterial occlusion, coronary artery disorder | Beijing Anzhen Hospital | Unknown | No outcome recorded |
| — | NCT04626973 Comparator | Jan 2021 → Sep 2025 | atherosclerotic cardiovascular disease | Yonsei University | Completed | No outcome recorded |
| — | NCT04656028 Background | Jun 2020 → Jan 2025 overdue | defective apolipoprotein b-100, hypercholesterolemia, autosomal dominant, 3, hypercholesterolemia, autosomal dominant, type B, hypercholesterolemia, familial, 1 +1 | National Medical Research Center for Therapy and Preventive Medicine | Active not recruiting | No outcome recorded |
| — | NCT03355027 Background | Nov 2017 → Sep 2019 | atherosclerosis | Cambridge University Hospitals NHS Foundation Trust | Unknown | No outcome recorded |
| — | NCT05306990 Comparator | Apr 2017 → Jun 2019 | type 2 diabetes mellitus | Helwan University | Completed | No outcome recorded |
| — | NCT03044665 Comparator | Mar 2017 → Jan 2022 | cerebrovascular disorder, peripheral arterial disease | Yonsei University | Unknown | No outcome recorded |
| — | NCT03127631 Comparator | Oct 2015 → Dec 2026 expected | cardiovascular disorder, prostate cancer | McMaster University | Active not recruiting | No outcome recorded |
| — | NCT01872845 Comparator | Jun 2013 → May 2017 | coronary artery disorder | Yonsei University | Completed | No outcome recorded |
| — | NCT01702987 Comparator | Oct 2012 → Oct 2013 | hyperlipidemia, myopathy, statin toxicity | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| — | NCT01623921 Comparator | Aug 2012 → Aug 2013 | acute respiratory distress syndrome | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| — | NCT01653119 Comparator | Apr 2012 → Jun 2015 | acute coronary syndrome, diabetes mellitus | Peking University Third Hospital | Unknown | No outcome recorded |
| — | NCT01173939 Comparator | Jul 2010 → Jun 2014 | hyperlipoproteinemia, hypertensive disorder, type 2 diabetes mellitus | Positive Trial Group | Terminated | No outcome recorded |
| — | NCT04328064 Comparator | May 2010 → May 2011 | Behcet disease | University of Alexandria | Completed | No outcome recorded |
| — | NCT00908011 Comparator | Jun 2009 → Dec 2014 | HIV infectious disease, hyperlipidemia | University of British Columbia | Completed | No outcome recorded |
| — | NCT01058915 Comparator | Nov 2007 → Jun 2009 | acute coronary syndrome | Odense University Hospital | Completed | No outcome recorded |
Evidence & citations 23 cited values
Every value below carries the sentence it was read from. 792 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rosuvastatin | “Ten healthy Caucasian subjects were orally dosed with the CIME combination (caffeine-CYP1A2, repaglinide-CYP2C8, tolbutamide-CYP2C9, omeprazole-CYP2C19,...” PMID 25465228 ↗ Dec 2014774“The purpose of this study is to determine whether administration of lapaquistat acetate co-administered with atorvastatin, rosuvastatin or simvastatin (stable statin therapy)...” NCT00249899 ↗ “Pharmacokinetics of a Fixed-Dose Combination Product of Amlodipine, Losartan, Ezetimibe, and Rosuvastatin and Its Comparison with Co-administration of Four Individual...” PMID 38775910 ↗ May 2024 “Usual dosage for atorvastatin 10-80 mg/tab once daily by mouth; simvastatin 20-80 mg/tab once daily by mouth; pravastatin 10-80 mg/tab once daily by mouth; rosuvastatin 5-20...” NCT00850460 ↗ “The study will evaluate the pharmacokinetics (PK) and safety effects of co-administration of radiprodil with oral midazolam, rosuvastatin, warfarin, digoxin, and omeprazole in...” NCT06975605 ↗ “Patients remained on ongoing statin therapy (not study provided) of either Atorvastatin 10mg or 20mg; Simvastatin 5mg, 10mg or 20mg; Rosuvastatin 5mg or 10mg; or Pravastatin...” NCT02072161 ↗ “The objective of this study was to evaluate the efficacy and tolerability of a triple combination of amlodipine/losartan/rosuvastatin in patients with hypertension and...” PMID 29150250 ↗ Nov 2017 “A Randomized, Open Label, Single Dose, 2X2 Cross-over Study to Compare Pharmacokinetics Between Rosuvastatin 10mg and Omega-3 1g Co-administration and HCP1007 in Healthy Male Volunteers” NCT01548157 ↗ “Treatment effect of olmesartan to hypertension and rosuvastatin to dyslipidemia is already proven in previous studies, and these medication does not have interaction with each other.” NCT04061824 ↗ “First line agents will be generic statin medications (atorvastatin or rosuvastatin)whichever is covered by the participant's health insurance), barring contraindication to their use.” NCT06975111 ↗ “The initial recommended therapy is 20mg atorvastatin/10mg rosuvastatin plus Ezetimibe or PCSK9i, and the type and dosage of drugs can be adjusted according to the situation.” NCT06896708 ↗ “DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin) X 1 tablet followed by Sevikar(Amlodipine/Olmesartan) X 1 tablet and Crestor(Rosuvastatin) X 1 tablet (after washout period)” NCT03753477 ↗ “Efficacy and Safety of a Fixed-Dose Combination of Candesartan and Rosuvastatin on Blood Pressure and Cholesterol in Patients With Hypertension and Hypercholesterolemia” PMID 31307833 ↗ Jul 2019 “Efficacy and Safety of Combined Cilostazol and Rosuvastatin Therapy Versus Rosuvastatin Alone in Patients with Chronic Lower Extremity Peripheral Artery Disease” NCT07600385 ↗ “The polypill will consist of a high-intensity statin (rosuvastatin 40 mg daily), aspirin 81 mg daily, and either clopidogrel 75 mg or prasugrel 10 mg daily.” NCT05514938 ↗ “Therefore, we sought to identify predictors of significant hsCRP reduction after the use of rosuvastatin (RSV)/amlodipine (AML) and atorvastatin (ATV)/AML.” PMID 40429358 ↗ May 2025 “Statin (pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin) at stable dose with or without other LMT as clinically indicated.” NCT02107898 ↗ “The polypill combines DAPT and a high intensity statin: (a) aspirin 81 mg, (b) rosuvastatin (40 or 10 mg) and (c) prasugrel 10 mg or clopidogrel 75 mg.” NCT07032389 ↗ “can be any of the following statins: rosuvastatin, atorvastatin, simvastatin, fluvastatin, pravastatin in any of the doses causing symptoms previously” NCT01259791 ↗ “Individuals deemed eligible through screening will be randomly assigned in a 1:1 ratio to either the rosuvastatin 2.5mg or rosuvastatin 10mg group.” NCT03770312 ↗ “The IMT-assigned women will receive high-dose, potent statin (atorvastatin 40-80 mg/d or rosuvastatin 20-40mg) class of lipid-lowering medications.” NCT03417388 ↗ “Oral administration of probe cocktail (Midazolam, Digoxin, Total Dabigatran etexilate, Rosuvastatin) in moderate fat/moderate calorie conditions.” NCT06533280 ↗ “telmisartan 40 mg/amlodipine 5 mg/rosuvastatin 10 mg (TEL/ALD/RSV) or amlodipine 5 mg/atorvastatin 10 mg (ALD/ATV) after washout/run-in period” PMID 38380420 ↗ Feb 2024 “Patients in the alirocumab arm will receive alirocumab 75 mg Q2W added to statin therapy (atorvastatin 20 mg/day or rosuvastatin 10mg/day).” NCT04851769 ↗ “Arm A had 30 participants receiving 200 mg cilostazol daily and arm B had 27 participants receiving 20 mg rosuvastatin daily for 7 days.” PMID 39487337 ↗ Nov 2024 “Statins (atorvastatin or rosuvastatin) at stable maximal tolerated dose of statin with or without other LMT as clinically indicated.” NCT01663402 ↗ “Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.” NCT01342211 ↗ “Examples of Medications that Meet Study Requirements: Atorvastatin 20mg Po qn, Rosuvastatin 10mg Po qn or Pitavastatin 4mg Po qn.” NCT06096909 ↗ “Multicenter, Prospective Adaptive Response Placebo-controlled Double-blind Study Comparing Effects of Rosuvastatin Versus Placebo” NCT01881971 ↗ “Vytorin (simvastatin 20mg/ezetimibe 10mg), Atozet (atorvastatin 20mg/ezetimibe 10mg), Cretrol (rosuvastatin 10mg/ezetimibe 10mg)” NCT07307989 ↗ “FDC drug (80 mg of telmisartan and 20 mg of rosuvastatin); (2) 80 mg of telmisartan; (3) 20 mg of rosuvastatin; or (4) placebo.” PMID 29673890 ↗ Apr 2018 “A moderate-intensity statin (rosuvastatin 5 mg) will be prescribed for patients over 75 years of age or with diabetes mellitus.” NCT05845424 ↗ “the administration of Alirocumab by Subcutaneous injection 75mg every 2 weeks plus Rosuvastatin10mg/daily by oral for 9 months” NCT03552432 ↗ “antiplatelet (aspirin or/and clopidogrel,100-300mg/d) and lipid-lowering (atorvastatin 20-60mg/d,rosuvastatin 10-20mg/d) drugs” NCT04581759 ↗ “Statin therapy includes rosuvastatin 20 mg administered orally, once a day, for the duration of the trial, which is 3 years.” NCT02114697 ↗ “The combination therapy group will receive a single-pill combination of rosuvastatin 10 mg and ezetimibe 10 mg once daily.” NCT04080310 ↗ “Statins (Rosuvastatin, Simvastatin or Atorvastatin) at stable dose with or without other LMT as clinically indicated.” NCT02289963 ↗ “Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.” NCT01954394 ↗ “Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.” NCT01507831 ↗ “Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.” NCT01617655 ↗ “Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.” NCT01623115 ↗ “telmisartan 80mg/rosuvastatin 10mg for ASCVD risk=5%\~7.5% or telmisartan 80mg/rosuvastatin 20mg for ASCVD risk≥7.5%” NCT03267329 ↗ “Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.” NCT01644175 ↗ “Statins include atorvastatin , fluvastatin , lovastatin , pitavastatin , pravastatin, rosuvastatin and simvastatin.” NCT06553157 ↗ “Atorvastatin 10 mg, 20 mg, or 40 mg, or rosuvastatin 5 mg, 10 mg, or 20 mg will be administered for up to 3 years.” NCT07359105 ↗ “Single subcutaneous (SC) dose of MBX 1416 and the single dose of rosuvastatin and acetaminophen pharmacokinetics.” NCT06036784 ↗ “The purpose of this study is to compare the drug interaction of pharmacokinetics of rosuvastatin and ezetimibe.” NCT02289430 ↗ “Atorvastatin 20 mg or Pitavastain 4 mg or Rosuvastatin 5 mg treatment initiated within 24 hours after admission” NCT02549846 ↗ “Rosuvastatin 20mg + Amlodipine 5mg (increased to Amlodipine 10mg if SBP \> 140mmHg or DBP \> 90mmHg at week 12)” NCT03474562 ↗ “Participants in this group will receive moderate-intensity statins (Atorvastatin 20 mg, Rosuvastatin 10 mg).” NCT06782243 ↗ “coadministration of Diovan® (Valsartan) 160 mg and Crestor® (Rosuvastatin) 20 mg in healthy male volunteers” NCT01918358 ↗ “All patients will be prescribed ezetimibe and statins (atorvastatin / rosuvastatin) at the maximum dosage.” NCT04656028 ↗ “All patients will receive moderate-intensity statin, including atorvastatin 20 mg or rosuvastatin 10 mg.” NCT06791031 ↗ “Atorvastatin, rosuvastatin and simvastatin at stable dose in participants with stable statin therapy” NCT01926782 ↗ “conventional lipid management (atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg)” NCT05397405 ↗ “a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension” PMID 32003938 ↗ Jan 2020 “Fixed-dose combination drug containing Amlodipine 5 mg and Valsartan 160 mg and Rosuvastatin 10 mg” NCT03009474 ↗ “rosuvastatin 5 mg (R5, n = 68), rosuvastatin 10 mg (R10, n = 67), rosuvastatin 20 mg (R20, n = 69)” PMID 31727361 ↗ Nov 2019 “Intensive statin could choose either Atorvastatin 40mg/day or Rosuvastatin 20mg/day, for 26 weeks” NCT05585151 ↗ “Both groups were treated with Rosuvastatin 40 mg as high potency statin for one month after PCI.” NCT04923152 ↗ “to either "atorvastatin 40 mg daily" or "rosuvastatin 40 mg + ezetimibe 10 mg daily" treatment.” NCT05368545 ↗ “ABT-143 (rosuvastatin 5 mg in combination with fenofibric acid 135 mg) once daily for 8 weeks” NCT00812955 ↗ “The lipid-lowering component will be initiated with rosuvastatin 10 mg plus ezetimibe 10 mg.” NCT07679828 ↗ “Statin treatment (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) for 1 month.” NCT03610321 ↗ “BGB-3111 and Drug Cocktail (midazolam, warfarin, omeprazole, digoxin and rosuvastatin)” NCT03561298 ↗ “Day 3: Single oral dose of transporter substrates (digoxin 0.25 mg, rosuvastatin 5 mg)” NCT05657613 ↗ “Single administration of a combination tablet of Rosuvastatin 20mg and Olmesartan 40mg” NCT01823900 ↗ “Rosuvastatin 40 mg daily may be substituted if patient is intolerant to atorvastatin.” NCT07586540 ↗ “All statins, e.g. atorvastatin, simvastatin, fluvastatin, rosuvastatin, pravastatin” NCT01634906 ↗ “high-intensity statin strategy (standard arm): rosuvastatin 20 mg PO qd, once daily” NCT05579626 ↗ “Any statin allowed (i.e. rosuvastatin, simvastatin, pravastatin, atorvastatin etc)” NCT01972178 ↗ “Period 1: One single dose of rosuvastatin and one single dose of digoxin on Day 1.” NCT05763459 ↗ “After SRP, 1.2% Rosuvastatin (RSV) gel was delivered subgingivally into the pocket” NCT02600520 ↗ “* rosuvastatin: 25 µg/mL and atorvastatin: 50 µg/mL given as 2mL oral solution” NCT04764851 ↗ “a fixed-dose combination of ezetimibe/rosuvastatin 10/20 mg, telmisartan 80 mg” PMID 33647189 ↗ Mar 2021 “Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)” NCT03707899 ↗ “high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily)” NCT07699003 ↗ “Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug” NCT01918709 ↗ “triple-combination of olmesartan/amlodipine/rosuvastatin (Olme/Amlo/Rosu)” PMID 37814541 ↗ Jan 2023 “Medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn)” NCT05298475 ↗ “randomly assigned to receive 10 mg of rosuvastatin or placebo per day” PMID 17984166 ↗ Nov 2007 “Digoxin 0.25 mg, furosemide 1 mg, metformin 10 mg, rosuvastatin 10 mg” NCT04233437 ↗ “Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose.” NCT01644188 ↗ “Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)” NCT06225635 ↗ “rosuvastatin 10 mg plus fenofibrate 160 mg or rosuvastatin 10 mg.” PMID 22269152 ↗ Jan 2012 “dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam” NCT05334108 ↗ “Atorvastatin at a dose of 80 mg./ Rosuvastatin 40 mg / day” NCT05624658 ↗ “monolayer combination of Gemigliptin/Rosuvastatin 50/20mg” NCT03867942 ↗ “rosuvastatin 10-20mg qd with or without ezetimibe 10mg qd” NCT04968509 ↗ “* Month 0-36: Rosuvastatin 10 mg qd + Ezetimibe 10 mg qd” NCT07432516 ↗ “oral administration of rosuvastatin (20 mg, once daily)” NCT05457582 ↗ “rosuvastatin calcium tablets (10 mg three times daily)” NCT07074834 ↗ “reload of rosuvastatin 40 mg before the procedure” NCT01228227 ↗ “Monorova® Tab (rosuvastatin 10mg) qd for 8 weeks” NCT03446261 ↗ “Rosuvastatin 10mg qn or atorvastatin 20mg qn” NCT06902740 ↗ “Ezetimibe 10mg / Rosuvastatin 20mg (Rosuzet)” NCT04081844 ↗ “Increased dose of rosuvastatin to 20mg/day” NCT00908011 ↗ “Rosuvastatin + Omega-3-acids ethyl esters” NCT02551172 ↗ “fimasartan(60mg,QD)+rosuvastatin(5mg,QD)” NCT02378064 ↗ “Ezetimibe 10mg/Rosuvastatin Ca 20.8mg” NCT04185090 ↗ “Rosuvastatin 10mg + Ezetimibe 10mg” NCT06767345 ↗ “Rosuvastatin (Crestor) 40mg daily” NCT01567826 ↗ “Rosuvastatin 20mg qd for 24 weeks” NCT03403556 ↗ “Rosuvastatin 10mg/Ezetimibe 10mg” NCT03597412 ↗ “Rosuvastatin 10mg/Ezetimibe 10mg” NCT03494270 ↗ “crestor 20mg(rosuvastatin 20mg)” NCT02060019 ↗ “rosuvastatin up to 20 mg daily” NCT00127218 ↗ “Rosuvastatin Calcium 20mg, QD” NCT03026933 ↗ “Rosuvastatin/Ezetimib 20/10mg” NCT05910476 ↗ “tablet, rosuvastatin 20mg” NCT01964365 ↗ “tablet, rosuvastatin 20mg” NCT01493856 ↗ “Rosuvastatin 10mg PO q24h” NCT05565976 ↗ “digoxin, and rosuvastatin” NCT03720366 ↗ “Rosuvastatin (to 20mg)” NCT02850081 ↗ “rosuvastatin 20mg” NCT06767774 ↗ “Rosuvastatin” NCT00249899 ↗ “Rosuvastatin” NCT00300482 ↗ “Rosuvastatin” NCT01702987 ↗ “Rosuvastatin” NCT04434365 ↗ “rosuvastatin” NCT01890967 ↗ “rosuvastatin” NCT01699126 ↗ “Rosuvastatin” NCT03074630 ↗ “Rosuvastatin” NCT01563731 ↗ |
| Known as | AZD4522 | “Rosuvastatin (AZD4522)” NCT01164540 ↗ |
| Known as | Cresnon | “Rosuvastatin(Cresnon®)” NCT02280590 ↗ |
| Known as | Cresto | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01415466 ↗ |
| Known as | Crestor | “The purpose of the study is to investigate the effects of atorvastatin (Lipitor) and rosuvastatin (Crestor), United States Food and Drug Administration (FDA) approved drugs...” NCT00115830 ↗42“Both drugs have been in use for decades for gout and pericarditis (colchicine) and hyperlipidemia, coronary disease (CAD) and diabetes (rosuvastatin/Crestor), and have been...” NCT04472611 ↗ “Pharmacodynamics and Pharmacokinetics of Combined Use of Rosuvastatin (Crestor) and Lopinavir/Ritonavir (Kaletra) in HIV-infected Patients With Hyperlipidemia (ROSALKA)” NCT00184951 ↗ “Name of Drugs: Niaspan (niacin extended-release tablets), Lipitor® (atorvastatin), Zocor® (simvastatin), Zetia™ (ezetimibe), and Crestor® (rosuvastatin)” NCT00079638 ↗ “The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year” NCT00296374 ↗ “co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Crestor Tab. 20mg(Rosuvastatin 20mg) and placebo of Olmesartan 40mg” NCT03009487 ↗ “A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome” NCT00240305 ↗ “Rosuvastatin (Crestor) was chosen as the study drug over others for pharmacokinetic and side effect profile.” NCT00978419 ↗ “single-dose rosuvastatin (Crestor®), a sensitive Breast Cancer Resistance Protein (BCRP) Substrate” NCT02300363 ↗ “Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin) followed by DWJ1351” NCT02665832 ↗ “Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)” NCT03247140 ↗ “Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)” NCT03707899 ↗ “40 patients will receive Crestor (Rosuvastatin 20mg/day orally for 6 months).” NCT06105060 ↗ “This is an open-label study of Rosuvastatin (Crestor) in patients with FRDA.” NCT02705547 ↗ “Lipitor (brand name for Atorvastatin), Crestor (brand name for Rosuvastatin)” NCT06782243 ↗ “Crestor® 40 mg Tablets containing Rosuvastatin Calcium 40 mg” NCT02962310 ↗ “Subjects take Statin(Crestor) 10mg per day for a- year” NCT02785874 ↗ “qd PO, Micardis(telmisartan) + Crestor(rosuvastatin)” NCT03210532 ↗ “Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab” NCT01925300 ↗ “Crestor(Rosuvastatin) and Micardis(Telmisartan)” NCT01992601 ↗ “CRESTOR, reference formulation of rosuvastatin” NCT03949374 ↗ “rosuvastatin 10 mg (Crestor®, Astra Zeneca)” NCT05072405 ↗ “rosuvastatin [Crestor] 10, 20, or 40 mg” PMID 20136164 ↗ 2010 “Rosuvastatin, also known as Crestor” NCT03532139 ↗ “Rosuvastatin (Crestor) 40mg daily” NCT01567826 ↗ “Crestor 20mg(Rosuvastatin 20mg)” NCT01975961 ↗ “2. Crestor 20 mg PO daily” NCT01455935 ↗ “Rosuvastatin (Crestor)” NCT06804980 ↗ “Rosuvastatin (Crestor)” NCT00525824 ↗ “Rosuvastatin(Crestor®)” NCT02280590 ↗ “crestor(Rosuvastatin)” NCT02089399 ↗ “Rosuvastatin-Crestor” NCT00464503 ↗ “Crestor” NCT00532311 ↗ |
| Known as | CRESTOR (brand name for rosuvastatin) | “CRESTOR (brand name for rosuvastatin)” NCT00658463 ↗ |
| Known as | Crestor (rosuvastatin calcium) | “Crestor® (rosuvastatin calcium)” NCT01899027 ↗ |
| Known as | Crestor 10mg(Rosuvastatin) | “Crestor 10mg(Rosuvastatin)” NCT01992211 ↗ |
| Known as | Crestor Tablet 20 mg manufactured by Astrazeneca | “Crestor Tablet 20 mg manufactured by Astrazeneca” NCT01466608 ↗ |
| Known as | Monorova Tab | “Monorova® Tab (rosuvastatin 10mg) qd for 8 weeks” NCT03446261 ↗ |
| Known as | R= Rosuvastatin = brand name : Crestor | “R= Rosuvastatin = brand name : Crestor” NCT01918709 ↗ |
| Known as | Rosu | “triple-combination of olmesartan/amlodipine/rosuvastatin (Olme/Amlo/Rosu)” PMID 37814541 ↗ Jan 2023 |
| Known as | rosuvastatin (Crestor) | “rosuvastatin (Crestor)” NCT00127218 ↗ |
| Known as | Rosuvastatin Calcium | “The combination product will be a Drug (Rosuvastatin calcium 5 mg) and Software as a Medical Device (Web App that features a Technology-Assisted Self-Selection (TASS) tool).” NCT04964544 ↗9“a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)” NCT03216304 ↗ “Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)” NCT06225635 ↗ “Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab” NCT01925300 ↗ “Rosuvastatin Calcium 20mg, QD” NCT03026933 ↗ “Drug: Rosuvastatin Calcium” NCT05828303 ↗ “Drug: rosuvastatin calcium” NCT01078675 ↗ |
| Known as | Rosuvastatin calcium Tablets | “Rosuvastatin calcium Tablets, 10 mg, once a night, orally.” NCT07309042 ↗ |
| Known as | ROVASRO | “ROVASRO, generic formulation of rosuvastatin” NCT03949374 ↗ |
| Known as | RSV | “The aim of this study was to evaluate the blood pressure-lowering and cholesterol-lowering effects of a fixed-dose combination therapy using candesartan (CND)/rosuvastatin...” PMID 31307833 ↗ Jul 201910“The present study aims to explore the efficacy of 1.2% rosuvastatin (RSV) gel local drug delivery as an adjunct to SRP in smokers with chronic periodontitis (CP).” NCT03043196 ↗ “Therefore, we sought to identify predictors of significant hsCRP reduction after the use of rosuvastatin (RSV)/amlodipine (AML) and atorvastatin (ATV)/AML.” PMID 40429358 ↗ May 2025 “The present study evaluated the efficacy of N-acetyl cysteine (NAC) and rosuvastatin (RSV) compared with conventional vitamin E in patients with NASH.” PMID 40480879 ↗ Jun 2025 “Rosuvastatin (RSV) is one of new synthetic, second-generation, sulfur-containing, hydrophilic statin” NCT02283515 ↗ “fimasartan 60 mg/amlodipine 10 mg + rosuvastatin 20 mg (FMS/ALD + RSV) as study group” PMID 36451242 ↗ Dec 2022 “After SRP, 1.2% Rosuvastatin (RSV) gel was delivered subgingivally into the pocket” NCT02600520 ↗ “The aim of this study was to evaluate the efficacy of rosuvastatin (RSV)” PMID 23323877 ↗ Feb 2013 “Rosuvastatin (RSV) is one of the most potent statins.” NCT02284503 ↗ “subgingival delivery of 1.2% Rosuvastatin (RSV) gel” NCT02985099 ↗ “rosuvastatin 20 mg (RSV) alone.” PMID 28057081 ↗ Jan 2017 |
| Known as | SUVAROODT | “Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg” NCT06153433 ↗ |
| Known as | Suvast | “Suvast tablet 10 mg (Rosuvastatin 10 mg)” NCT04700436 ↗ |
| Action | Inhibit | “rosuvastatin treatment downregulates LPS-induced inflammatory responses, serum hsCRP, and monocyte TLR4 expression” NCT00295373 ↗ |
| Modality | Small molecule | “treatment with statins” PMID 19810001 ↗ Sep 2009 |
| Route | Oral | “Oral” NCT00239681 ↗ |
| Target | HMGCR | “the HMG-CoA reductase inhibitor Rosuvastatin” NCT00505154 ↗ |